Handling of GCP inspection by FDA and comparison with GCP inspection by EMA

Shigeki Nishihara, Satoshi Kuroda, Kumiko Ueda, Yu Hitobe, Akihito Higashikage, Toshimitsu Konuma, Kaori Yukiyoshi, Hiroto Okuda, Yuta Tanaka, Yoshihisa Kitamura, Koji Abe, Toshiaki Sendo

研究成果査読

抄録

We report our experience with GCP inspection by FDA. Prior to the inspection, preparations were made by conducting a preliminary consultation with the client and a mock inspection. The inspection by FDA was conducted by one inspector for a duration of 8 days. The inspection revealed no problem. Compared with the GCP inspection by EMA that we received previously, the GCP inspection by FDA involved the same procedures of confirming the documents related to the clinical trial, including all the primary outcomes and adverse events. The two inspections differed in the number of inspectors and the inspection schedule. Based on the experience with the FDA and EMA inspections, construction of quality control system in medical institutions is considered necessary.

本文言語English
ページ(範囲)231-235
ページ数5
ジャーナルJapanese Journal of Clinical Pharmacology and Therapeutics
49
6
DOI
出版ステータスPublished - 2018

ASJC Scopus subject areas

  • 薬理学
  • 薬理学(医学)

フィンガープリント

「Handling of GCP inspection by FDA and comparison with GCP inspection by EMA」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル